A multimodal precision-prevention approach combining lifestyle intervention with metformin repurposing to prevent cognitive impairment and disability: the MET-FINGER randomised controlled trial protocol
Mariagnese Barbera,Jenni Lehtisalo,Dinithi Perera,Malin Aspö,Mary Cross,Celeste A De Jager Loots,Emanuela Falaschetti,Naomi Friel,José A Luchsinger,Hanna Malmberg Gavelin,Markku Peltonen,Geraint Price,Anna Stigsdotter Neely,Charlotta Thunborg,Jaakko Tuomilehto,Francesca Mangialasche,Lefkos Middleton,Tiia Ngandu,Alina Solomon,Miia Kivipelto,MET-FINGER study team,Seliat Adebanke Adeleke,Clara Arvidsson,Isobel Barton,Mehmet Bas,Katrina Cosby,Jennifer Crispin,Lucy Dunn,Margarita Durkina,Ottilia Elebring,Jamie Ford,Parthenia Giannakopoulou,Hanne Gilkes,Hannah Graham,Göran Hagman,Ruby Hall,Helena Hallinder,Arzish Haqqee,Maris Hartmanis,Katri Hemiö,Zuzana Istvánfyová,Dimitra Kafetsouli,Kristina Lakey,Saara Lehtimäki,Lotta Lindström,Peter MacDonald,Aaro Mäkelä,Stefan McGinn-Summers,Carolina Meius,Amnah Mirza,Christine Oesterling,Joanna Ojala,Abdulwarrith Olawale,Isabela Ramanath,Hanna-Maria Roitto,Bilal Sahib,Shonella Singh,Maria Sundell,Shannon Taylor,Devika Tharumaratnam,Kerttu Uusimäki,Johanna Vaarala,Heta Voutilainen,Jessica Åsander
DOI: https://doi.org/10.1186/s13195-023-01355-x
2024-01-31
Abstract:Background: Combining multimodal lifestyle interventions and disease-modifying drugs (novel or repurposed) could provide novel precision approaches to prevent cognitive impairment. Metformin is a promising candidate in view of the well-established link between type 2 diabetes (T2D) and Alzheimer's Disease and emerging evidence of its potential neuro-protective effects (e.g. vascular, metabolic, anti-senescence). MET-FINGER aims to test a FINGER 2.0 multimodal intervention, combining an updated FINGER multidomain lifestyle intervention with metformin, where appropriate, in an APOE ε4-enriched population of older adults (60-79 years) at increased risk of dementia. Methods: MET-FINGER is an international randomised, controlled, parallel-group, phase-IIb proof-of-concept clinical trial, where metformin is included through a trial-within-trial design. 600 participants will be recruited at three sites (UK, Finland, Sweden). Participants at increased risk of dementia based on vascular risk factors and cognitive screening, will be first randomised to the FINGER 2.0 intervention (lifestyle + metformin if eligible; active arm) or to receive regular health advice (control arm). Participants allocated to the FINGER 2.0 intervention group at risk indicators of T2D will be additionally randomised to receive metformin (2000 mg/day or 1000 mg/day) or placebo. The study duration is 2 years. The changes in global cognition (primary outcome, using a Neuropsychological Test Battery), memory, executive function, and processing speed cognitive domains; functional status; lifestyle, vascular, metabolic, and other dementia-related risk factors (secondary outcomes), will be compared between the FINGER 2.0 intervention and the control arm. The feasibility, potential interaction (between-groups differences in healthy lifestyle changes), and disease-modifying effects of the lifestyle-metformin combination will be exploratory outcomes. The lifestyle intervention is adapted from the original FINGER trial (diet, physical activity, cognitive training, monitoring of cardiovascular/metabolic risk factors, social interaction) to be consistently delivered in three countries. Metformin is administered as Glucophage®XR/SR 500, (500 mg oral tablets). The metformin/placebo treatment will be double blinded. Conclusion: MET-FINGER is the first trial combining a multimodal lifestyle intervention with a putative repurposed disease-modifying drug for cognitive impairment prevention. Although preliminary, its findings will provide crucial information for innovative precision prevention strategies and form the basis for a larger phase-III trial design and future research in this field. Trial registration: ClinicalTrials.gov (NCT05109169).